A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorRDC Clinical Pty Ltd
About this trial
The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \& Flu Blend in reducing the duration of symptoms of the common cold. The secondary objective is to assess whether the investigational product reduces the severity of symptoms. Participants will be enrolled for 16 weeks, during this period they will take the assigned study product when they experience URTI symptoms.
Eligibility criteria
Qualifiers
Adults aged 18-65 years living in Australia
Individuals with a history of recurrent Upper Respiratory Tract infections (URTI) (at least one episode per year)
Able to provide informed consent
Generally healthy
Disqualifiers
Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, autoimmune conditions, neurological disorders such as multiple sclerosis.
Unstable illness e.g., changing medication/treatment.
BMI <18.5, >30
Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.
Trial design
Treatments tested in this trial
- Novel Herbal Cold & Flu Blend
- Placebo
Treatment groups
300 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
RDC Clinical Pty Ltd
Lead sponsor
iNova Pharmaceuticals
Collaborator
Source ClinicalTrials.gov